Achondroplasia Pipeline Analysis report covers drugs of 6 companies currently in different phases of development. Achondroplasia is a bone growth disorder which is caused by a mutation in the FGFR3 gene. It is normally observed that during early fetal development, most of the skeleton is made up of cartilage which eventually changes into bone. In a person suffering from achondroplasia, there will be no conversion of cartilage into the bone giving rise to disproportionate dwarfism. FGFR3 gene is responsible for guiding the human body in making a protein which is necessary for the normal growth of the bone and its maintenance. However, the mutation in the gene causes the protein to be overactive interfering with normal skeletal development.
The report provides achondroplasia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are BioMarin, Therachon, Ribomic Inc., Ascendis Pharma A/S, QED Therapeutics (BridgeBio Inc.), and Catalent, Inc.